Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: ARM Hit By iPhone Production Cut Report

Wed, 06th Jan 2016 10:18

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.
----------
FTSE 100 - WINNERS
----------
Royal Mail, up 1.9%. Barclays upgraded the postal service operator to Overweight from Equal Weight and hiked its price target to 575 pence from 440p. Royal Mail shares were trading at 444.80p. The bank expects a new pay deal to be negotiated in the first quarter of 2016 and for the company to resolve the issues around its defined benefit pension scheme by the second half. Barclays also said it was confident the cost-cutting measures Royal Mail is taking will keep costs broadly flat, allowing any rise in revenue to feed through to the bottom line. It is the second vote of confidence in Royal Mail shares in as many days. Cantor Fitzgerald upgraded the postal operator to Buy from Hold on Tuesday.

BAE Systems, up 1.9%. RBC Capital Markets upgraded its rating on BAE Systems to Top Pick from Outperform, hiking its target price to 630 pence from 570p. BAE was trading at 501p.
----------
FTSE 100 - LOSERS
----------
ARM Holdings, down 3.0%. The company, which designs semiconductors that are used in Apple's iPhones, was hit after a report in Japan's Nikkei Asian Review said Apple is expected to reduce the output of iPhone 6s and 6s Plus models by around 30% in the January-March quarter compared with its original plans. The report said inventories of the two models, which launched last September, have piled up at retailers in markets ranging from China and Japan to Europe and the US amid lackluster sales. Customers saw little improvement in performance over the previous generation, while dollar appreciation led to sharp price hikes in emerging markets.
----------
FTSE 250 - WINNERS
----------
Card Factory, up 0.9%. Card Factory has appointed Karen Hubbard as its chief executive designate, with effect from February 22. The greeting cards and gifts retailer hired Hubbard from discount retailer B&M European Value Retail, where she has been chief operating officer since 2014. Prior to this, she worked in a number of roles at Asda, the Wal-Mart Stores-owned UK supermarket chain, including heading its property, format development and multi-channel business. She will take over from Card Factory's current chief executive, Richard Hayes, in mid-April. The company also said Christmas trading had been in line with its expectations.
----------
FTSE 250 - LOSERS
----------
Home Retail Group, down 4.5%. The owner of Argos and Homebase gave back some gains made on Tuesday, when it closed up 34% following the news FTSE 100-listed grocer J Sainsbury had made an unsolicited bid for the company in November, which Home Retail rejected. Home Retail has been the subject of speculation about a potential takeover offer ever since its shares slumped in October following a profit warning, hit by investments in restructuring the business and slower-than-expected trading. Sainsbury's shares were down 0.9%.
----------
MAIN MARKET AND AIM - WINNERS
----------
Sula Iron & Gold, up 22%. The miner said its chief executive said the assay results from the recent drilling campaign on the Ferensola gold project in Sierra Leone exceeded his expectations and leads him to believe there is a major high-grade deposit. "I am excited by the results of the second batch of drill core samples from the extended scout drilling programme at our Ferensola Gold Project, together with the samples of 'goldstones' as they exceed my best-case expectations," said Nick Warrel.

Corero Network Security, up 15%. The security systems developer said it has secured a USD700,000 order for its SmartWall Threat Defense System product from an undisclosed European internet service provider. Under the order Corero will provide protection against distributed denial of service attacks, a form of hack that makes on online service unavailable by overwhelming it with traffic from multiple sources, as a service for one of the ISP's "high profile" customers.

Midatech Pharma, up 12%. The specialty pharmaceutical company said 2015 revenue will be "slightly ahead of expectations" following its recent acquisitions of Dara BioSciences and Zuplenz, and it also forecast revenue growth at the higher end of market forecasts for 2016. "Following the acquisition of DARA BioSciences and Zuplenz, and further licensing and supply agreements, 2015 has shown significant growth for Midatech, achieving the strategic objectives set out at the time of the IPO and accelerating the company towards sustainable profitability," said Chief Executive Officer Jim Phillips in a statement.
----------
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.